Lipopolysaccharide

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Integra LifeSciences Holdings Corporation (IART)

Retrieved on: 
Monday, September 25, 2023
Integra, Lipopolysaccharide, Suite, PMA, Court, Defendant, FDA, GPM, News, Pharmaceutical industry

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • On this news, Integra’s stock price fell $4.64, or 7.9%, to close at $54.20 per share on April 26, 2023, thereby injuring investors.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles

Lifshitz Law PLLC Announces Investigations of Integra LifeSciences Holdings Corporation (NASDAQ: IART), Enviva, Inc. (NYSE: EVA), and DigitalOcean Holdings, Inc. (NYSE: DOCN), and Lumen Technologies, Inc. (NYSE: LUMN)

Retrieved on: 
Sunday, September 24, 2023
Lumen, Telephone, Integra, Lipopolysaccharide, Lead, Boston, EVA, Advertising, Risk, FDA, Environment, Hewlett, Cryptocurrency, Online shopping

The Company also extended the pause on all production at the Boston Facility.

Key Points: 
  • The Company also extended the pause on all production at the Boston Facility.
  • The Company further disclosed that it expected to take a $22 million impairment charge in the second quarter due to the inventory write-off.
  • These disclosures caused the price of Integra stock to decline by an additional $10.24 per share, or 20%.
  • The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516)493-9780.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against PacWest, DigitalOcean, and Integra and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, September 23, 2023
Complaint, Kleffman v. Vonage Holdings Corp., PMA, Patient, News, NYSE, P.C, Letter, Lipopolysaccharide, DigitalOcean, FDA, Shareholder, Disclosure, Integra, PWB, Defendant, PacWest, PacWest Bancorp, Infection, Audit, Dietary supplement, Pharmaceutical industry

Most significantly, the FDA found that Integra failed to adequately test for bacterial endotoxins in the medical devices manufactured at the Boston Facility.

Key Points: 
  • Most significantly, the FDA found that Integra failed to adequately test for bacterial endotoxins in the medical devices manufactured at the Boston Facility.
  • The Company further disclosed that it expected to take a $22 million impairment charge in the second quarter due to the inventory write-off.
  • These disclosures caused the price of Integra stock to decline by an additional $10.24 per share, or 20%.
  • For more information on the Integra class action go to: https://bespc.com/cases/IART

INTEGRA LIFESCIENCES INVESTOR ALERT: Kaplan Fox & Kilsheimer LLP Notifies Integra LifeSciences Investors of a Class Action Lawsuit and Upcoming Deadline

Retrieved on: 
Friday, September 22, 2023
FOX, Integra, Lipopolysaccharide, Kaplan Fox, Complaint, Notice, Patient, Risk, Regulation of tobacco by the U.S. Food and Drug Administration, News, Food, Medical device

If you acquired Integra common stock during the Class Period and would like to discuss this case, please click here.

Key Points: 
  • If you acquired Integra common stock during the Class Period and would like to discuss this case, please click here.
  • WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey.
  • With over 50 years of experience in complex litigation, Kaplan Fox offers the professional experience and track record that clients demand.
  • For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com .

INTEGRA LIFESCIENCES HOLDING CORPORATION (NASDAQ: IART) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Integra LifeSciences Holding Corporation

Retrieved on: 
Wednesday, September 20, 2023
Integra, Lipopolysaccharide, District court, Advertising, Complaint, Court, Action Replay, News, Security (finance), Pharmaceutical industry, Tobacco

NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:

Key Points: 
  • NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:
    Do you, or did you, own shares of Integra LifeSciences Holding Corporation (NASDAQ: IART)?
  • Did you lose money in your investment in Integra LifeSciences Holding Corporation?
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Integra Lifesciences Holdings Corporation (IART) Investor Alert: Robbins LLP Reminds Investors of Class Action Filed Against Integra Lifesciences Holdings Corporation

Retrieved on: 
Monday, September 18, 2023
Complaint, LLP, Integra, Lipopolysaccharide, Boston, FDA, PMA, News, SAN, Person, Dietary supplement, Pharmaceutical industry

SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons or entities that purchased or otherwise acquired Integra Lifesciences Holdings Corporation (NASDAQ: IART) common stock between March 11, 2019 and May 22, 2023.

Key Points: 
  • SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons or entities that purchased or otherwise acquired Integra Lifesciences Holdings Corporation (NASDAQ: IART) common stock between March 11, 2019 and May 22, 2023.
  • For more information, submit a form , email Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • However, Integra had failed to take sufficient measures to remediate the violations identified by the FDA.
  • What Now: Similarly situated shareholders may be eligible to participate in the class action against Integra Lifesciences Holdings Corporation.

Integra Lifesciences Holdings Corporation (IART) Class Action Notice: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Integra Lifesciences Holdings Corporation Securities Fraud Class Action

Retrieved on: 
Friday, September 22, 2023
Class Action Lawsuit, Professional Services, Legal, Complaint, LLP, Integra, Lipopolysaccharide, Boston, FDA, PMA, News, Person, Dietary supplement, Pharmaceutical industry

For more information, submit a form , email Aaron Dumas, Jr., or give us a call at (800) 350-6003.

Key Points: 
  • For more information, submit a form , email Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • What Now: Similarly situated shareholders may be eligible to participate in the class action against Integra Lifesciences Holdings Corporation.
  • Shareholders who want to act as lead plaintiff for the class must file their motion for lead plaintiff by November 13, 2023.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Integra LifeSciences Holdings Corporation (IART)

Retrieved on: 
Thursday, September 21, 2023
Class Action Lawsuit, Professional Services, Legal, Integra, Lipopolysaccharide, Suite, PMA, Court, Defendant, FDA, GPM, News, Pharmaceutical industry

Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming November 13, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Integra LifeSciences Holdings Corporation (“Integra” or the “Company”) (NASDAQ: IART ) common stock between March 11, 2019 and May 22, 2023, inclusive (the “Class Period”).

Key Points: 
  • Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming November 13, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Integra LifeSciences Holdings Corporation (“Integra” or the “Company”) (NASDAQ: IART ) common stock between March 11, 2019 and May 22, 2023, inclusive (the “Class Period”).
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • On this news, Integra’s stock price fell $4.64, or 7.9%, to close at $54.20 per share on April 26, 2023, thereby injuring investors.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Integra LifeSciences Holdings Corporation (IART)

Retrieved on: 
Wednesday, September 20, 2023
Class Action Lawsuit, Professional Services, Legal, Telephone, Integra, Lipopolysaccharide, Law, Suite, PMA, Defendant, Court, FDA, News, Security (finance), Pharmaceutical industry

Investors suffering losses on their Integra investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to [email protected] .

Key Points: 
  • Investors suffering losses on their Integra investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to [email protected] .
  • On this news, Integra’s stock price fell $4.64, or 7.9%, to close at $54.20 per share on April 26, 2023, thereby injuring investors.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Integra LifeSciences Holdings Corporation (IART) Investors

Retrieved on: 
Tuesday, September 19, 2023
Class Action Lawsuit, Professional Services, Legal, Integra, Lipopolysaccharide, Suite, PMA, Court, Defendant, FDA, GPM, News, Pharmaceutical industry

Integra investors have until November 13, 2023 to file a lead plaintiff motion.

Key Points: 
  • Integra investors have until November 13, 2023 to file a lead plaintiff motion.
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • On this news, Integra’s stock price fell $4.64, or 7.9%, to close at $54.20 per share on April 26, 2023, thereby injuring investors.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.